Thienorphine is an oripavine with long-lasting antinociceptive effects in mice that are thought to be mediated by μ-opioid receptors. This study examined the receptor binding of thienorphine in cell membrane homogenates and its behavioral effects in rhesus monkeys (Macaca mulatta). Affinity and potency were determined using radioligand displacement and stimulation of guanosine 5′-O-(3-[35S]thio)triphosphate binding in C6 (μ, δ) and Chinese hamster ovary (κ) cell membranes. Thienorphine displayed high affinity for κ-, μ-, and δ-opioid receptors with Ki values of 0.14, 0.22, and 0.69 nM, respectively. Thienorphine partially stimulated κ-opioid (75%) and μ-opioid (19%) receptors and not δ-opioid receptors. Thienorphine dose-dependently increased tail-withdrawal latency for 50°C water and not 55°C water with effects lasting for more than 7 days. The κ-opioid receptor antagonist nor-binaltorphimine (nor-BNI) (3.2 mg/kg) and a large dose (1.0 mg/kg) of naltrexone prevented thienorphine-induced antinociception. Thienorphine enhanced the antinociceptive effects of morphine and U50,488 [trans-3, 4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide] with 50°C water; with 55°C water, thienorphine enhanced the effects of morphine and attenuated the effects of U50,488. In other monkeys, thienorphine decreased responding in both components of a multiple schedule of food presentation and stimulus shock termination for up to 8 days; naltrexone and nor-BNI partially prevented these rate-decreasing effects. In morphine-treated monkeys discriminating naltrexone, thienorphine, and U50,488 neither substituted for nor modified the naltrexone discriminative stimulus. Thienorphine and U50,488 produced the same directly observable signs. These results show that thienorphine has long-lasting effects that seem to be mediated by low-efficacy agonism at κ-opioid receptors, both in vitro and in vivo.
|Original language||English (US)|
|Number of pages||10|
|Journal||Journal of Pharmacology and Experimental Therapeutics|
|State||Published - Apr 2007|
ASJC Scopus subject areas
- Molecular Medicine